Kennedy Capital Management’s Gilead Sciences GILD Stock Holding History

Kennedy Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.7M	Sell	91,264 -4,139	-4%	-$580K	0.27%	135
2025 Q4	$11.7M	Buy	95,403 +1,128	+1%	+$137K	0.25%	150
2025 Q3	$10.5M	Buy	94,275 +15,234	+19%	+$1.73M	0.23%	150
2025 Q2	$8.76M	Sell	79,041 -41	-0.1%	-$4.36K	0.21%	164
2025 Q1	$8.86M	Sell	79,082 -3,931	-5%	-$406K	0.21%	163
2024 Q4	$7.67M	Buy	83,013 +16,603	+25%	+$1.49M	0.17%	203
2024 Q3	$5.57M	Buy	66,410 +5,023	+8%	+$383K	0.12%	285
2024 Q2	$4.21M	Buy	61,387 +21,167	+53%	+$1.41M	0.09%	362
2024 Q1	$2.95M	Buy	+40,220	New	+$3.09M	0.06%	449

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Kennedy Capital Management's GILD Position: Q1 2026 in Review

Kennedy Capital Management reduced its Gilead Sciences (GILD) stake by 4.3% in Q1 2026, selling an estimated $580K and leaving 91,264 shares worth $12.7M. The position accounts for 0.27% of the portfolio, ranked #135.

Kennedy Capital Management first reported a position in GILD in Q1 2024 and has held it in 9 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Kennedy Capital Management held 91,264 shares of Gilead Sciences worth $12.7M as of Q1 2026.
Kennedy Capital Management sold 4,139 Gilead Sciences shares in Q1 2026, an estimated $580K.
Gilead Sciences made up 0.27% of Kennedy Capital Management's portfolio in Q1 2026, its #135 holding.
Kennedy Capital Management first reported a position in Gilead Sciences in Q1 2024 and has held it in 9 quarters since.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.